A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy

Albert Grinshpun; Irit Merlet; Hila Fruchtman; Dean Nachman

doi:10.3389/fonc.2020.01085

Frontiers in Oncology (Jun 2020)

A Protracted Course of COVID19 Infection in a Metastatic Breast Cancer Patient During CDK4/6 Inhibitor Therapy

Albert Grinshpun,
Irit Merlet,
Hila Fruchtman,
Dean Nachman

Affiliations

Albert Grinshpun: Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Irit Merlet: Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Hila Fruchtman: Radiology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel
Dean Nachman: Internal Medicine A, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

DOI: https://doi.org/10.3389/fonc.2020.01085
Journal volume & issue: Vol. 10

Abstract

Read online

We describe the first case report of a patient with COVID19 infection and metastatic breast cancer, while on systemic therapy with a CDK4/6 inhibitor. The patient had unique disease course, characterized with delayed symptomatology. The case highlights novel findings and stress careful and extended follow-up during COVID19 infection in patients taking biologic therapies affecting the immune system.

Published in Frontiers in Oncology

ISSN: 2234-943X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.frontiersin.org/journals/oncology/

About the journal

Abstract

Keywords